To determine whether simvastatin reduces serum markers of brain injury and lessens vasospasm after SAH.
- Simvastatin Drug
Intervention Desc: HMG-CoA reductase inhibitor; lowers cholesterol
Randomized, double-blind, placebo-controlled trial.
Patients with angiographically documented aneurysmal SAH were randomized within 48 hours of symptom onset to receive either simvastatin (80 mg daily; n=19) or placebo (n=20) for 14 days. Plasma alanine aminotransferase, aspartate aminotransferase, and creatine phosphokinase were recorded weekly to evaluate laboratory evidence of hepatitis or myositis. Serum markers of brain injury were recorded daily.
|Type||Measure||Time Frame||Safety Issue|
|Primary||The primary end point of vasospasm was defined as clinical impression (delayed ischemic deficit not associated with rebleed, infection, or hydrocephalus) in the presence of >/=1 confirmatory radiographic test (angiography or transcranial Doppler demonstrating mean VMCA >160 m/sec).|